News
Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...
The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...
Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...
AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...
The AI-focused biotech insitro has laid off 22% of its workforce, the company said in a Thursday statement. Founded ...
After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...
BMS commits $40B for US expansion, Shionogi buys Torii Pharma for $1.05B, Bavarian Nordic extends BARDA deal, multiple ...
'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis
Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...
Los Angeles-based health system Cedars-Sinai is partnering with venture studio Redesign Health to build health tech startups ...
President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...
A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results